Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biosimilar Interchangeability: Stakeholders Want More FDA Guidance, Fewer Hurdles

Executive Summary

The limited discussion of interchangeability in FDA’s initial biosimilar draft guidances has left some stakeholders clamoring for more details. Others say the agency’s demand for a “higher standard” of evidence to show interchangeability is misplaced and will inhibit use of the 351(k) pathway.


Related Content

Biosimilar Guidances: Broader Populations Permitted; More Immunogenicity Requested
FDA Wants Biosimilar Naming Guidance Released Before Approving An Application
Biosimilars: Does Low BsUFA Fee Revenue Suggest Sponsor Interest Has Stalled?
How To Get A Meeting With FDA: Guidance Describes Formal Meetings For Biosimilars
Sandoz Pushing FDA To Make Biosimilar Interchangeability Decisions
Korea’s Samsung Biologics Halts Rituxan Biosimilar Trials To Meet U.S, EU Standards
Biosimilar Podium Promotion: FDA Emphasizes Advantages Of Abbreviated Pathway
FDA Biosimilars Guidances Address Immunogenicity Studies, European Bridge Data, Analytics
Waxman Says Biosimilar Pathway Will Push Applicants To BLA
Biosimilars May Drift, But What Should FDA Do About It?


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts